| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-136 |
| filingDate |
2018-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111110849-B |
| titleOfInvention |
Application of serine protease inhibitor Kazal 1 in preparation of cell aging and tumor diagnosis or regulation preparation |
| abstract |
The invention relates to an application of a serine protease inhibitor Kazal 1 type factor (SPINK1) in preparation of a preparation for diagnosing or regulating cell senescence and tumors. It was first revealed that SPINK1 plays an important biological role in the SASP phenotype as well as in the tumor microenvironment, which is closely related to prognosis following chemotherapy treatment. Therefore, SPINK1 can be used as a target for SASP phenotype regulation research and tumor microenvironment-based anti-tumor research, as a marker for prognosis evaluation and grading of tumors after chemotherapy treatment, and as a target for developing tumor-inhibiting drugs. |
| priorityDate |
2018-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |